Genflow Biosciences (LSE:GENF) announced it had broadened the legal perimeter around its SIRT6 gene‑therapy platform with the international publication of PCT application WO 2026/062177 A1.
The move pushes protection for SIRT6 beyond longevity and metabolic uses and explicitly into muscular diseases, a space tied to ageing and high unmet need. The published application covers variants of SIRT6 for the prevention and treatment of muscular diseases, with particular focus on frailty syndrome and sarcopenia.
It describes compositions and methods including nucleic acids, polypeptides, vectors and pharmaceutical compositions intended for use in muscular disease settings associated with loss of muscle mass and altered endocrine function of the muscle.
Genflow framed the publication as a strategic step to "build layered protection" around therapeutic uses of SIRT6 and to preserve the ability to seek patents across multiple jurisdictions
The company lead candidate, GF‑1002, delivers a centenarian variant of SIRT6 and the company began a proof‑of‑concept clinical trial in aged dogs in March.
"The international publication of this patent application marks another important step in the expansion of Genflow's intellectual property portfolio. By extending our SIRT6 platform into muscular diseases such as frailty and sarcopenia, we are continuing to build strategic protection around areas of high unmet need and significant relevance to healthy ageing. This publication further strengthens our position as we advance the development and potential partnering of our gene therapy platform," said CEO Dr Eric Leire.
